Immuneering (IMRX) EBIT: 2020-2023
Historic EBIT for Immuneering (IMRX) over the last 4 years, with Dec 2023 value amounting to -$16.3 million.
- Immuneering's EBIT fell 16.57% to -$16.3 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$58.4 million, marking a year-over-year decrease of 12.89%. This contributed to the annual value of -$58.4 million for FY2023, which is 12.89% down from last year.
- Per Immuneering's latest filing, its EBIT stood at -$16.3 million for Q4 2023, which was down 17.06% from -$13.9 million recorded in Q3 2023.
- In the past 5 years, Immuneering's EBIT registered a high of -$3.2 million during Q2 2020, and its lowest value of -$16.3 million during Q4 2023.
- For the 3-year period, Immuneering's EBIT averaged around -$12.0 million, with its median value being -$13.1 million (2022).
- Data for Immuneering's EBIT shows a maximum YoY crashed of 146.69% (in 2021) over the last 5 years.
- Quarterly analysis of 4 years shows Immuneering's EBIT stood at -$5.8 million in 2020, then crashed by 90.45% to -$11.1 million in 2021, then fell by 25.81% to -$14.0 million in 2022, then declined by 16.57% to -$16.3 million in 2023.
- Its EBIT was -$16.3 million in Q4 2023, compared to -$13.9 million in Q3 2023 and -$13.5 million in Q2 2023.